Implementation barriers remain largely programmatic, requiring integrated HIV testing, adherence support, STI services, and ...
The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by 2nd February next year. If approved, the oral ...
Gilead Sciences, Inc. GILD announced that the FDA has accepted its supplemental new drug application (sNDA) for Yeztugo ...
Clinical Trials Arena on MSN
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials
Gilead and MSD will be filing the data from the Phase III trials of the once-weekly HIV pill to regulatory authorities.
Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...
Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...
(Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo ® (lenacapavir) 300-mg tablet as a potential once-weekly ...
Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...
Advances in treatment of HIV have improved the health and quality of life for so many. Advances in treatment of the disease have improved the health and quality of life for countless individuals.
The ministry of Health says demand for Lenacapavir, the newly introduced twice-yearly HIV prevention injection, has exceeded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results